AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8949620 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg and caffeine 50 mg
Number of subjects: 124
Study 8949620 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 400 mg and dextropropoxyphene 30 mg
Number of subjects: 124
Study 1957847 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle biopsy
Number of subjects: 275
Study 1957847 — intervention group
Group type: COMPARATOR
Intervention: Novak biopsy
Number of subjects: 275
Study 1957847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 275
Study 7178369 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg i.v.)
Number of subjects: 6
Study 7178369 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg i.v.) plus Phentolamine (60 mg i.v.)
Number of subjects: 6
Study 30878234 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free DES
Number of subjects: 326
Study 30878234 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer DES
Number of subjects: 326
Study 31735178 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal fascia graft plus platelet-rich fibrin therapy
Number of subjects: 91
Study 31735178 — intervention group
Group type: COMPARATOR
Intervention: Temporal fascia graft alone
Number of subjects: 91
Study 27001374 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of two implants supporting mandibular overdentures (T2)
Number of subjects: 30
Study 27001374 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of two implants supporting mandibular overdentures (T3)
Number of subjects: 30
Study 26023213 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐week Internet‐based pain coping skills training (PCST) protocol in addition to a 24‐week standardized intervention comprising an 8‐week Internet‐based education package followed by 5 individual physical therapy exercise sessions plus home exercises (3 times weekly)
Number of subjects: 142
Study 26023213 — intervention group
Group type: COMPARATOR
Intervention: 24‐week standardized intervention comprising an 8‐week Internet‐based education package followed by 5 individual physical therapy exercise sessions plus home exercises (3 times weekly)
Number of subjects: 142
Study 24029300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 8
Study 22673937 — intervention group
Group type: EXPERIMENTAL
Intervention: DHR (12 × 5min bouts, 10% decline at 85% VO(2)max)
Number of subjects: 10
Study 22673937 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 10
Study 20043830 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-tailored education and distribution of LLINs (1 or 2 per household)
Number of subjects: 132
Study 17634479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in EGFR low group (n = 113)
Number of subjects: 564
Study 17634479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in EGFR high group (n = 73)
Number of subjects: 564
Study 17634479 — intervention group
Group type: COMPARATOR
Intervention: Untreated EGFR low group
Number of subjects: 564
Study 15561731 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 10845
Study 15561731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10845
Study 11754853 — intervention group
Group type: COMPARATOR
Intervention: Posterior mediastinal route
Number of subjects: 6
Study 9679845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate powder (50 microg or 100 microg twice daily)
Number of subjects: 437
Study 9679845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 8210253 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) administered by drip infusion for 2 hours (group A)
Number of subjects: 41
Study 8210253 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) administered by bolus injection (group B)
Number of subjects: 41
Study 8210253 — intervention group
Group type: COMPARATOR
Intervention: Comparison of gastrointestinal toxicity
Number of subjects: 41
Study 8210253 — intervention group
Group type: COMPARATOR
Intervention: Leukocytopenia severity
Number of subjects: 41
Study 8210253 — intervention group
Group type: COMPARATOR
Intervention: Alopecia frequency
Number of subjects: 41
Study 3513884 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 250 mg for four weeks
Number of subjects: 2
Study 3513884 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 250 mg for four weeks
Number of subjects: 2
Study 3513884 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2
Study 30094517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical facilitation (ICF) using 110% intensity of the test stimulus (TS)
Number of subjects: 48
Study 30094517 — intervention group
Group type: COMPARATOR
Intervention: Short intracortical inhibition (SICI)
Number of subjects: 48
Study 30094517 — intervention group
Group type: COMPARATOR
Intervention: Long intracortical inhibition (LICI)
Number of subjects: 48
Study 27250831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program with voluntary pelvic floor muscle contraction (PFMC)
Number of subjects: 57
Study 27250831 — intervention group
Group type: COMPARATOR
Intervention: Pilates exercise program without voluntary pelvic floor muscle contraction (PFMC)
Number of subjects: 57
Study 25170796 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium 30 mg/day + Solifenacin 10 mg/day
Number of subjects: 177
Study 25170796 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium 15 mg/day + Solifenacin 5 mg/day
Number of subjects: 177
Study 25170796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 22398088 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly + Calcium (500 mg) + Vitamin D (400 IU)
Number of subjects: 88
Study 22398088 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Calcium (500 mg) + Vitamin D (400 IU)
Number of subjects: 88
Study 22398088 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate + Calcium + Vitamin D
Number of subjects: 88
Study 20196149 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) therapy at a dosage of 5 mg/kg intravenously at weeks 0, 2, 6, and every 8 weeks thereafter
Number of subjects: 40
Study 20196149 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) therapy
Number of subjects: 40
Study 18569264 — intervention group
Group type: EXPERIMENTAL
Intervention: dechloro ethylcloprostenolamide (Group A: 1.69 mm)
Number of subjects: 34
Study 18569264 — intervention group
Group type: EXPERIMENTAL
Intervention: dechloro ethylcloprostenolamide (Group B: 1.94 mm)
Number of subjects: 34
Study 18569264 — intervention group
Group type: EXPERIMENTAL
Intervention: dechloro ethylcloprostenolamide (Group D: 1.44 mm)
Number of subjects: 34
Study 18569264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C: 0.63 mm)
Number of subjects: 34
Study 18554862 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (200 mg/day)
Number of subjects: 0
Study 18554862 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol (2 mg/day)
Number of subjects: 0
Study 18554862 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of soy isoflavones and 17-beta-estradiol
Number of subjects: 0
Study 18554862 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones tested directly and indirectly (metabolized)
Number of subjects: 0
Study 15050262 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld keratometry with subjects in lying posture and with artificial tears
Number of subjects: 35
Study 15050262 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld keratometry with subjects in sitting posture and with artificial tears
Number of subjects: 35
Study 15050262 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld keratometry with subjects in lying posture without artificial tears
Number of subjects: 35
Study 15050262 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld keratometry with subjects in sitting posture without artificial tears
Number of subjects: 35
Study 15050262 — intervention group
Group type: COMPARATOR
Intervention: Topographic keratometry
Number of subjects: 35
Study 10790463 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by nurses
Number of subjects: 1163
Study 10790463 — intervention group
Group type: COMPARATOR
Intervention: Pediatric clinic visits by nurse practitioners or physicians
Number of subjects: 1163
Study 9348446 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclear lens
Number of subjects: 42
Study 9348446 — intervention group
Group type: COMPARATOR
Intervention: Permaflex lens
Number of subjects: 42
Study 8244135 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg gliadin (group A)
Number of subjects: 20
Study 8244135 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg gliadin (group B)
Number of subjects: 20
Study 3513568 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folic acid (250 mg per day for 3 months)
Number of subjects: 5
Study 3513568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 5
Study 3513568 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folic acid (250 mg per day for an additional 3 months)
Number of subjects: 5
Study 31916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcystic biliary drainage
Number of subjects: 310
Study 31916605 — intervention group
Group type: COMPARATOR
Intervention: No transcystic drainage (control)
Number of subjects: 310
Study 31304600 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose regimen (1500 IU anti-D at 28 weeks)
Number of subjects: 277
Study 31304600 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose regimen (625 IU anti-D at 28 and 34 weeks)
Number of subjects: 277
Study 31304600 — intervention group
Group type: COMPARATOR
Intervention: Single dose regimen
Number of subjects: 277
Study 31304600 — intervention group
Group type: COMPARATOR
Intervention: Two-dose regimen
Number of subjects: 277
Study 29849845 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed intranasal Morphine ARER
Number of subjects: 0
Study 29849845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact oral Morphine ARER
Number of subjects: 0
Study 29849845 — intervention group
Group type: COMPARATOR
Intervention: Crushed intranasal ER morphine
Number of subjects: 0
Study 29849845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact oral Morphine ARER and crushed intranasal Morphine ARER
Number of subjects: 0
Study 29849845 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine ARER
Number of subjects: 0
Study 27776098 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal blockade with 10 mL of bupivacaine 0.25% with epinephrine 1:300,000
Number of subjects: 40
Study 27776098 — intervention group
Group type: COMPARATOR
Intervention: Normal saline adductor canal block
Number of subjects: 40
Study 24370568 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen at 1.5 ATA (1.5 ATAO2)
Number of subjects: 60
Study 24370568 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen at 2.0 ATA (2.0 ATAO2)
Number of subjects: 60
Study 24370568 — intervention group
Group type: COMPARATOR
Intervention: Sham Air
Number of subjects: 60
Study 22371239 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT-A (Dysport) 500 U
Number of subjects: 163
Study 22371239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 19786514 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit intervention program
Number of subjects: 90
Study 19786514 — intervention group
Group type: COMPARATOR
Intervention: Standard health care
Number of subjects: 90
Study 17259258 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water and pulsating negative pressure treatment (NM group)
Number of subjects: 20
Study 17259258 — intervention group
Group type: COMPARATOR
Intervention: Forced-air warming (SM group)
Number of subjects: 20
Study 15081453 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel fatty acid supplement
Number of subjects: 0
Study 11167480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Buscopan 20 mg
Number of subjects: 44
Study 11167480 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 44
Study 9571344 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LIS) injected 20 min before the meal
Number of subjects: 18
Study 9571344 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LIS) injected immediately before the meal
Number of subjects: 18
Study 9571344 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LIS) injected 15 min after the meal
Number of subjects: 18
Study 9571344 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (REG) injected 40 min before the meal
Number of subjects: 18
Study 9571344 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (REG) injected 20 min before the meal
Number of subjects: 18
Study 9571344 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (REG) injected immediately before the meal
Number of subjects: 18
Study 7831946 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Infusion system (Haemonetics Corp., Braintree, MA)
Number of subjects: 20
Study 7831946 — intervention group
Group type: COMPARATOR
Intervention: Conventional iv volume administration (37 degrees C) using pressure infusion bags
Number of subjects: 20
Study 2905134 — intervention group
Group type: EXPERIMENTAL
Intervention: metaclazepam
Number of subjects: 9
Study 2905134 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 29917226 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2017
Number of subjects: 465
Study 29917226 — intervention group
Group type: COMPARATOR
Intervention: ref-ADMB
Number of subjects: 465
Study 27630501 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-hydroxyapatite composite graft
Number of subjects: 15
Study 27630501 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite-placebo gel composite graft
Number of subjects: 15
Study 26341720 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise training (RT)
Number of subjects: 117
Study 26341720 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training in combination with nutrient supplementation (RTS)
Number of subjects: 117
Study 26341720 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 117
Study 23754545 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine 800 mg twice daily for 10 days every month
Number of subjects: 96
Study 23754545 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 96
Study 20942278 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with nerve block
Number of subjects: 90
Study 20942278 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 90
Study 20942278 — intervention group
Group type: COMPARATOR
Intervention: Nerve block
Number of subjects: 90
Study 18391662 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer-based learning (CBL) courses
Number of subjects: 0
Study 18391662 — intervention group
Group type: COMPARATOR
Intervention: Text-only courses
Number of subjects: 0
Study 18391662 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CBL courses
Number of subjects: 0
Study 16608953 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 ppm for 12 hours
Number of subjects: 30
Study 16608953 — intervention group
Group type: COMPARATOR
Intervention: Control (no inhaled nitric oxide)
Number of subjects: 30
Study 16608953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (iNO and control)
Number of subjects: 30
Study 11753136 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs that modulate the inflammatory response in interstitial cystitis
Number of subjects: 0
Study 10421236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of [1‐13C]alanine for 3.5 hours
Number of subjects: 12
Study 10421236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube infusion of [1‐13C]alanine for 3.5 hours
Number of subjects: 12
Study 10421236 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IV and NG infusion
Number of subjects: 12
Study 10421236 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of enteral alanine
Number of subjects: 12
Study 7547087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg with food
Number of subjects: 21
Study 7547087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg with antacid (Maalox)
Number of subjects: 21
Study 7547087 — intervention group
Group type: COMPARATOR
Intervention: Tenidap sodium 120 mg fasting
Number of subjects: 21
Study 2179584 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered bacterial extract
Number of subjects: 70
Study 2179584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 6106500 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 0
Study 6106500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 0
Study 6106500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30667365 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal instability (CIN) in pancreatic NET
Number of subjects: 225
Study 30667365 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal instability (CIN) in gastrointestinal NET
Number of subjects: 225
Study 28351374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training (WMT) with active personalized coaching and feedback for 8 weeks, 4 days a week, 30 minutes a day.
Number of subjects: 52
Study 28351374 — intervention group
Group type: COMPARATOR
Intervention: Cogmed Working Memory Training (WMT) without personalized coaching (general non-personalized coaching) for 8 weeks, 4 days a week, 30 minutes a day.
Number of subjects: 52
Study 25886536 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum postoperatively and standard care
Number of subjects: 0
Study 25886536 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution and standard care
Number of subjects: 0
Study 23278131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulathromycin IM
Number of subjects: 108
Study 23278131 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline monotherapy PO
Number of subjects: 108
Study 23278131 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline with rifampin PO
Number of subjects: 108
Study 23278131 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin with rifampin PO
Number of subjects: 108
Study 23278131 — intervention group
Group type: COMPARATOR
Intervention: Saline IM (placebo)
Number of subjects: 108
Study 23278131 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-rifampin
Number of subjects: 108
Study 21367495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glucose intake (2.5 mg kg(‐1) min(‐1))
Number of subjects: 17
Study 21367495 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose intake (5.0 mg kg(‐1) min(‐1))
Number of subjects: 17
Study 21367495 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard amino acid intake (1.5 g kg(‐1) day(‐1))
Number of subjects: 17
Study 21367495 — intervention group
Group type: COMPARATOR
Intervention: High amino acid intake (3.0 g kg(‐1) day(‐1))
Number of subjects: 17
Study 21367495 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (80 mU m(‐2) min(‐1))
Number of subjects: 17
Study 19722799 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + Xan‐CHX gel treatment
Number of subjects: 98
Study 19722799 — intervention group
Group type: COMPARATOR
Intervention: SRP treatment
Number of subjects: 98
Study 17711540 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 microg fluticasone (Accuhaler) plus 800 microg budesonide (Turbohaler) after induced bronchoconstriction
Number of subjects: 20
Study 17711540 — intervention group
Group type: COMPARATOR
Intervention: 1000 microg fluticasone (Accuhaler) plus 800 microg budesonide (Turbohaler) without induced bronchoconstriction
Number of subjects: 20
Study 15004830 — intervention group
Group type: EXPERIMENTAL
Intervention: 585 nm/0.5 milliseconds
Number of subjects: 15
Study 15004830 — intervention group
Group type: EXPERIMENTAL
Intervention: 595 nm/20 milliseconds
Number of subjects: 15
Study 15004830 — intervention group
Group type: COMPARATOR
Intervention: 595 nm/0.5 milliseconds
Number of subjects: 15
Study 11572292 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH‐Spectrum
Number of subjects: 52
Study 11572292 — intervention group
Group type: EXPERIMENTAL
Intervention: Compoglass
Number of subjects: 52
Study 9280178 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed oil (average ALA intake: 5.9 g/d)
Number of subjects: 46
Study 9280178 — intervention group
Group type: COMPARATOR
Intervention: Fish oil plus sunflower oil (average EPA + DHA intake: 5.2 g/d)
Number of subjects: 46
Study 8393884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (oral)
Number of subjects: 13
Study 8393884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 13
Study 3089519 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (2‐4 micrograms given intramuscularly at 8 pm)
Number of subjects: 5
Study 31433058 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 117
Study 28475159 — intervention group
Group type: EXPERIMENTAL
Intervention: 600,000 IU cholecalciferol (VD group)
Number of subjects: 24
Study 28475159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL group)
Number of subjects: 24
Study 26003683 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) 4 × 0.8 g day(‐1)
Number of subjects: 80
Study 26003683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; soybean oil)
Number of subjects: 80
Study 23080358 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PrEP
Number of subjects: 72
Study 23080358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent PrEP
Number of subjects: 72
Study 23080358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 21649935 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a rapid response service that assesses and treats the patient at home
Number of subjects: 0